Improving the outlook for TP53-aberrant CLL

Blood. 2021 Nov 11;138(19):1785-1786. doi: 10.1182/blood.2021012759.

Author

Michael Y Choi¹

Affiliation

¹ University of California San Diego Moores Cancer Center.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Chromosome Deletion
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Tumor Suppressor Protein p53 / genetics

Substances

TP53 protein, human
Tumor Suppressor Protein p53